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LETTERS TO THE EDITOR
New Tumor, Node,
Metastasis Staging
System for Lung
Cancer
To the Editor:
Recently, the International Asso-
ciation for the Study of Lung Cancer has
registered patients with lung cancer, di-
agnosed and treated between 1990 and
2000, in relation to evaluative stages
according to the tumor, node, metastasis
system, and its changes applied from
2002 in the 6th review worldwide has
been accepted.
Not only the English version but
also the Spanish1,2 one shows that the
validation of a new proposal, motivated
by the changes seen in the rates of sur-
vival in different clinical stages, has not
considered a phenomenon called “Will
Rogers”3 that occurs when newer tech-
nologies were used.
This phenomenon, initially be-
cause of a philosopher humorist in 1930,
is a manifest bias of patient’s identifica-
tion diagnosed with a new procedure
and its survival and seems to be inap-
propriately longer only because its dis-
ease had been diagnosed before.
The new technology leads to a
stage migration and apparent improve-
ment in patient survival. As the possi-
bility of this phenomenon occurs, which
has not been mentioned in the articles
cited, it is interesting to notice its sub-
liminal presence and not establish better
survival rates that it does not exist. I
would like to have an analysis about this
opinion.
Eduardo B. Arribalzaga, MD, PhD
Thoracic Surgery Division
Hospital de Clínicas
Buenos Aires, Argentina
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In Response:
The letter to the editor by Arrib-
alzaga1 on the potential influence of the
Will Rogers phenomenon in the analy-
ses of the data of the International As-
sociation for the Study of Lung Cancer
(IASLC) database raises a relevant clin-
ical issue that is difficult to assess in a
retrospective study. The initial phase of
the IASLC Lung Cancer Staging Project
was retrospective, and specific informa-
tion on the tests used for tumor staging
was not available. When the Interna-
tional Staging Committee of the IASLC
discussed the period during which the
retrospective data were to be collected,
the period between 1990 and 2000 was
considered ideal. It was thought that
computed tomography had been widely
used in the geographic areas of the con-
tributing institutions (Asia, Australia,
Europe, and North America), and that
the newer positron emission tomogra-
phy, on the other hand, had been seldom
used. It was also thought that staging
techniques had not varied much during
those years, and therefore, the Will Rog-
ers phenomenon would have had a very
minor effect, if any. A way to compen-
sate for the possible effect of this phe-
nomenon was the extensive validation
process applied to the findings that fi-
nally lead to recommending changes:
internal validation by geographic area
and type of database and external vali-
dation by the replication of findings in
the Surveillance, Epidemiology and End
Results registries for the same period.2
In any case, the survival rates for clini-
cal and pathologic stages found in the
analyses of the IASLC database repre-
sent survival for contemporary lung can-
cer patients that has been consistently
reproduced in different geographic and
research settings,3 and they are very
similar (survival is even worse for some
stages) to those reported by Mountain4
in 1997 (Table 1). Compared with the
Mountain database of slightly more than
5000 surgically treated patients col-
lected during more than 20 years, the
period of accrual of the IASLC database
was extremely short (10 years) for such
a large database of more than 100,000
patients. Additionally, the IASLC Lung
Cancer Staging Project was a global
effort that included patients treated by
all modalities of care, perhaps less influ-
enced by the Will Rogers phenomenon
than surgically treated cases. Although
the effect of the Will Rogers phenome-
non cannot be ruled out completely, it is
likely to be small.
The second phase of the IASLC
Lung Cancer Staging Project is prospec-
tive and has already started in 2009. Its
results will inform the eighth edition of
the tumor, node, metastasis classifica-
tion for lung cancer of 2016, and, if data
are complete, will allow assessing the
influence of the tests used for tumor
staging.5 A part of the prospective data-
set is dedicated to record these tests,
grouped according to the certainty factor
Disclosure: The authors declare no conflict of
interest.
Address for correspondence: Eduardo B. Arribal-
zaga, MD, PhD, Co´rdoba 2351 8°, Ciudad
Autonoma de Buenos Aires, 1122 Argentina.
E-mail: piedralta@gmail.com
Copyright © 2009 by the International Association
for the Study of Lung Cancer
ISSN: 1556-0864/09/0410-1301
Disclosure: The authors declare no conflicts of
interest.
Copyright © 2009 by the International Association
for the Study of Lung Cancer
ISSN: 1556-0864/09/0410-1301
TABLE 1. Five-Yr Survival Rates by
Clinical and Pathologic Stages in the
Mountain4 and IASLC Series3
Stages
Mountain
Stages
IASLC Proposed
Stages
Clinical
(%)
Pathologic
(%)
Clinical
(%)
Pathologic
(%)
IA 61 67 50 73
IB 38 57 43 58
IIA 34 55 36 46
IIB 24 39 25 36
IIIA 13 23 19 24
IIIB 5 NA 7 9
IV 1 NA 2 13
NA, not available.
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(C factor) recommended by the Interna-
tional Union Against Cancer.6 If great
differences are found in the use of stag-
ing tests among the institutions that par-
ticipate in the prospective project, re-
sults could be stratified by the certainty
factor of the staging process. If survival
was significantly better for those pa-
tients whose tumors had been staged
with more intensity than for those with
tumors in the same stage but staged with
lower certainty factor, this would pro-
vide an indication of the effect of the
Will Rogers phenomenon and would
validate prospectively the staging rele-
vance of the certainty factor.
We thank Dr. Arribalzaga for
bringing to the attention of the readers
the Will Rogers phenomenon in relation
with the recent proposals for changes in
the tumor, node, metastasis classifica-
tion of lung cancer.
Ramon Rami-Porta, MD
Thoracic Surgery Service
Hospital Universitario Mutua de Terrassa
Barcelona, Spain
Peter Goldstraw, MB, FRCS
Department of Thoracic Surgery
Royal Brompton Hospital and Imperial
College
London, United Kingdom
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